title: Usefulness of Everolimus-Eluting Coronary Stent Implantation in Patients on Maintenance Hemodialysis.
abstract: The outcomes of second-generation drug-eluting stent (DES) are unknown in patients on maintenance hemodialysis (HD) although HD has been reported as a strong predictor of adverse outcome after the first-generation DES implantation. The OUCH-PRO Study is a prospective multicenter single-arm registry design to study clinical and angiographic outcomes after everolimus-eluting stent (EES). Patients who underwent maintenance HD were prospectively enrolled at the time of elective coronary intervention using EES. Quantitative coronary angiography was performed in an independent core laboratory. The primary end point was the occurrence of target vessel failure (TVF) defined as cardiac death, myocardial infarction (MI), and target vessel revascularization at 1 year. A total of 123 patients were enrolled and 161 EES were implanted. The TVF rate at 1 year was 18% (4% cardiac death, 0% MI, 17% target vessel revascularization). No stent thrombosis was documented. Other clinical events at 1 year were 3% noncardiac death, 3% stroke, and 9% non-target-vessel revascularization. Late lumen loss in stent was 0.37 ± 0.63 mm at 8 months. In conclusion, EES had a high TVF rate and great late lumen loss in patients on HD compared with previous huge EES data in non-HD patients.
authors.affiliation: Department of Cardiovascular Medicine, Tokai University School of Medicine, Isehara, Japan. Electronic address: ikari@is.icc.u-tokai.ac.jp.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ikari
authors.affiliation: Teikyo University Hospital, Tokyo, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kyono
authors.affiliation: Teikyo University Hospital, Tokyo, Japan.
authors.forename: Takaaki
authors.initials: T
authors.lastname: Isshiki
authors.affiliation: Toyohashi Heart Center, Toyohashi, Japan.
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ishizuka
authors.affiliation: Toyohashi Heart Center, Toyohashi, Japan.
authors.forename: Kenya
authors.initials: K
authors.lastname: Nasu
authors.affiliation: Iwatsuki Minami Hospital, Iwatsuki, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Sano
authors.affiliation: Seirei Hamamatsu Hospital, Hamamatsu, Japan.
authors.forename: Hisayuki
authors.initials: H
authors.lastname: Okada
authors.affiliation: Yokohama City University Hospital, Yokohama, Japan.
authors.forename: Teruyasu
authors.initials: T
authors.lastname: Sugano
authors.affiliation: Mito Brain Heart Center, Mito, Japan.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Uehara
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery*; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D011446:Prospective Studies; D012042:Registries; D006435:Renal Dialysis; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus